May 03,2023

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

Dexcom announced today the publication of a study "Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK" in Diabetes Therapy. The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits. Based on a willingness-to-pay threshold of £20,000 per quality-adjusted life year (QALY), the research found: 70.8% probability of rtCGM being cost-effective to the NHS compared to finger-pricking to test via a blood glucose meter and; 38.7% probability of rtCGM being cost-saving to the NHS as it can help decrease the risk of developing diabetes-related complications. The estimated yearly cost of diabetes to the NHS in 2022 is £10 billion – around 10% of its budget. rtCGM was associated with An incremental cost-effectiveness ratio of £3,684 per QALY versus testing with finger pricks.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 05,2023

Study supports feasibility of Know Labs non-invasive CGM

Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM. It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle. The company sought to validate the technical feasibility of its Bio-RFID sensor technology for quantifying blood glucose concentration (BGC). Its studies evaluated five healthy participants using the Dexcom G6 as a reference device. Participants placed their forearms on the Bio-RFID sensor and consumed liquid D-Glucose to stimulate a glucose spike. The study monitored BGC for three hours while simultaneously logging readings from the Bio-RFID sensor and the Dexcom G6. It collected data on a continuous basis. Know Labs then used the data from the Bio-RFID sensor to train the neural network model to predict the readings. Know Labs said its study resulted in a mean absolute relative difference (MARD) of 20.6%. It performed with 46% of predictions within the FDA’s recommended limit for accuracy for new blood glucose monitors.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 19,2023

Senseonics announces first pediatric 365-day CGM insertion

The insertion took place as part of the company’s ENHANCE clinical trial at the AMCR Institute. AMCR, a clinical research center, focuses on pre-diabetes, type 1, type 2 diabetes and obesity. The study operates under the direction of Dr. Timothy Bailey. Dr. Francine Kaufman, Senseonics CMO, said expanding to a pediatric population represents a “priority” for the company.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 17,2023

Tandem Diabetes Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes

Tandem Diabetes Care announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The analysis showed an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c compared to control groups in people ages 2 to 72 years old. People with the highest baseline blood sugar levels experienced the greatest benefit from the auto-bolus feature of the Control-IQ algorithm. Improvements in time in range for subjects using Control-IQ technology (n=256) were immediate, sustained, and observed across the spectrum of patient characteristics including age, race-ethnicity, parental education, family income, baseline glycated hemoglobin level, virtual vs. in-person training format, and pre-study insulin delivery method. The majority of the control group (n=113) used an insulin pump (91%), some with predictive low glucose suspend technology.

CLINICAL STUDY

#closed loop

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 02,2023

An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial

Researchers investigated the efficacy of an integrated digital health care platform with artificial intelligence (AI)–based dietary management in adults with type 2 diabetes (T2D). In this 48-week, open-label, randomized, multicenter clinical trial, overweight or obese adults with T2D were randomly assigned to one of three groups in a 1:1:1 ratio: group A received routine diabetes care; group B used the digital integrated health care platform by themselves; and group C used the platform with feedback from medical staff and intermittently applied personal continuous glucose monitoring. The decreases in HbA1c from baseline to 24 and 48 weeks in group B and group C were significantly larger than those in group A. Among adults with T2D, use of an integrated digital health care platform with AI-driven dietary management resulted in better glycemia and more weight loss.

CLINICAL STUDY

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

This implantable fuel cell generates electricity from glucose

A team of researchers developed an implantable fuel cell that uses excess glucose from tissue to generate electrical energy. By combining the fuel cell with artificial data cells, the team produced insulin with the touch of a button. This effectively lowered blood glucose levels like the natural process in the pancreas. Given that current treatments for diabetes often include insulin pumps that require a reliable energy supply, the team feels it may have found a new way to produce that energy.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

New Study from Teladoc Health Further Validates the Effectiveness of a Single, Integrated Care Experience

Teladoc Health, the global leader in whole-person virtual care, today released new findings from a peer-reviewed study showing individual improvements in A1c, systolic blood pressure and weight, when enrolled in multiple chronic condition management programs over time. Individuals participating only in a diabetes program with a self-reported A1c greater than 7% who then engaged with hypertension, weight management and mental health programs saw an additional reduction in A1c (0.44%). Individuals starting on the weight management program with a BMI greater or equal to 30 who then engaged in three programs, saw an additional 1.0% reduction in body weight.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. All participants were using a Dexcom G6 Continuous Glucose Monitoring (CGM) System. Mean time in range with Control-IQ technology increased from 57 percent at baseline to 69 percent during follow-up compared to 55 percent to 56 percent in the control group, for a mean adjusted difference of 12.4 percent. Nighttime mean time in range was 74 percent with Control-IQ technology versus 56 percent in the control group and daytime was 67 percent versus 56 percent, respectively.

CLINICAL STUDY

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

AI Predicts Cancer Patient Survival by Reading Doctor's Note

A team of researchers from the University of British Columbia and BC Cancer have developed an artificial intelligence (AI) model that predicts cancer patient survival more accurately and with more readily available data than previous tools. The model uses natural language processing (NLP) - a branch of AI that understands complex human language - to analyze oncologist notes following a patient’s initial consultation visit - the first step in the cancer journey after diagnosis. The model uses natural language processing (NLP) - a branch of AI that understands complex human language - to analyze oncologist notes following a patient’s initial consultation visit - the first step in the cancer journey after diagnosis.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

FREENOME PRESENTS A SUBJECT POPULATION ANALYSIS OF A CLINICAL STUDY USING A MULTIOMICS BLOOD TEST FOR THE EARLY DETECTION OF COLORECTAL CANCER

Today Freenome, a privately held biotech company, presents a subject population analysis from PREEMPT CRC, a study for the detection of colorectal cancer (CRC) at the Western Colorectal Cancer Consortium Conference in Portland, Oregon. The study's focus was to enroll subjects that reflected the demographics of the intended use population for a colorectal cancer screening test: average-risk adults between the ages of 45 and 85 across urban and rural communities in the United States. The company offered options of virtual enrollment, electronic consenting and mobile phlebotomy that enabled home blood draws for participants who were not geographically close or able to visit a hospital or other study site. Analysis of results demonstrate enrollment strategies were effective in recruiting an intended-use population. Freenome is in the final stages of development of its blood-based screening test for colorectal cancer. The test uses Freenome's multiomics platform, which combines tumor and non-tumor signals with machine learning to detect cancer in the earliest, most treatable stages using a standard blood draw. The test is intended to offer an accessible and convenient option for CRC screening.

CLINICAL STUDY

#ml

#software

#platform

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY